Genetically Engineered Islets and Alternative Sources of Insulin-Producing Cells for Treating Autoimmune Diabetes: Quo Vadis?
Islet transplantation is a promising therapy for patients with type 1 diabetes that can provide moment-to-moment metabolic control of glucose and allow them to achieve insulin independence. However, two major problems need to be overcome: (1) detrimental immune responses, including inflammation indu...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2012/296485 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552413235511296 |
|---|---|
| author | Feng-Cheng Chou Shing-Hwa Huang Huey-Kang Sytwu |
| author_facet | Feng-Cheng Chou Shing-Hwa Huang Huey-Kang Sytwu |
| author_sort | Feng-Cheng Chou |
| collection | DOAJ |
| description | Islet transplantation is a promising therapy for patients with type 1 diabetes that can provide moment-to-moment metabolic control of glucose and allow them to achieve insulin independence. However, two major problems need to be overcome: (1) detrimental immune responses, including inflammation induced by the islet isolation/transplantation procedure, recurrence autoimmunity, and allorejection, can cause graft loss and (2) inadequate numbers of organ donors. Several gene therapy approaches and pharmaceutical treatments have been demonstrated to prolong the survival of pancreatic islet grafts in animal models; however, the clinical applications need to be investigated further. In addition, for an alternative source of pancreatic β-cell replacement therapy, the ex vivo generation of insulin-secreting cells from diverse origins of stem/progenitor cells has become an attractive option in regenerative medicine. This paper focuses on the genetic manipulation of islets during transplantation therapy and summarizes current strategies to obtain functional insulin-secreting cells from stem/progenitor cells. |
| format | Article |
| id | doaj-art-151ee064d0134d37b69a4c0eb41a6202 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-151ee064d0134d37b69a4c0eb41a62022025-02-03T05:58:43ZengWileyInternational Journal of Endocrinology1687-83371687-83452012-01-01201210.1155/2012/296485296485Genetically Engineered Islets and Alternative Sources of Insulin-Producing Cells for Treating Autoimmune Diabetes: Quo Vadis?Feng-Cheng Chou0Shing-Hwa Huang1Huey-Kang Sytwu2Department and Graduate Institute of Microbiology and Immunology, National Defense Medical Center, Neihu, Taipei 114, TaiwanDepartment of General Surgery, Tri-Service General Hospital, Taipei 114, TaiwanDepartment and Graduate Institute of Microbiology and Immunology, National Defense Medical Center, Neihu, Taipei 114, TaiwanIslet transplantation is a promising therapy for patients with type 1 diabetes that can provide moment-to-moment metabolic control of glucose and allow them to achieve insulin independence. However, two major problems need to be overcome: (1) detrimental immune responses, including inflammation induced by the islet isolation/transplantation procedure, recurrence autoimmunity, and allorejection, can cause graft loss and (2) inadequate numbers of organ donors. Several gene therapy approaches and pharmaceutical treatments have been demonstrated to prolong the survival of pancreatic islet grafts in animal models; however, the clinical applications need to be investigated further. In addition, for an alternative source of pancreatic β-cell replacement therapy, the ex vivo generation of insulin-secreting cells from diverse origins of stem/progenitor cells has become an attractive option in regenerative medicine. This paper focuses on the genetic manipulation of islets during transplantation therapy and summarizes current strategies to obtain functional insulin-secreting cells from stem/progenitor cells.http://dx.doi.org/10.1155/2012/296485 |
| spellingShingle | Feng-Cheng Chou Shing-Hwa Huang Huey-Kang Sytwu Genetically Engineered Islets and Alternative Sources of Insulin-Producing Cells for Treating Autoimmune Diabetes: Quo Vadis? International Journal of Endocrinology |
| title | Genetically Engineered Islets and Alternative Sources of Insulin-Producing Cells for Treating Autoimmune Diabetes: Quo Vadis? |
| title_full | Genetically Engineered Islets and Alternative Sources of Insulin-Producing Cells for Treating Autoimmune Diabetes: Quo Vadis? |
| title_fullStr | Genetically Engineered Islets and Alternative Sources of Insulin-Producing Cells for Treating Autoimmune Diabetes: Quo Vadis? |
| title_full_unstemmed | Genetically Engineered Islets and Alternative Sources of Insulin-Producing Cells for Treating Autoimmune Diabetes: Quo Vadis? |
| title_short | Genetically Engineered Islets and Alternative Sources of Insulin-Producing Cells for Treating Autoimmune Diabetes: Quo Vadis? |
| title_sort | genetically engineered islets and alternative sources of insulin producing cells for treating autoimmune diabetes quo vadis |
| url | http://dx.doi.org/10.1155/2012/296485 |
| work_keys_str_mv | AT fengchengchou geneticallyengineeredisletsandalternativesourcesofinsulinproducingcellsfortreatingautoimmunediabetesquovadis AT shinghwahuang geneticallyengineeredisletsandalternativesourcesofinsulinproducingcellsfortreatingautoimmunediabetesquovadis AT hueykangsytwu geneticallyengineeredisletsandalternativesourcesofinsulinproducingcellsfortreatingautoimmunediabetesquovadis |